Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CLYM on Nasdaq
Shares outstanding
47,705,000
Price per share
$4.91
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
28,719,480
Total reported value
$114,894,226
% of total 13F portfolios
0%
Share change
-16,370,199
Value change
-$59,704,101
Number of holders
63
Price from insider filings
$4.91
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 33% $36,086,101 17,953,284 RA Capital Management, L.P. 11 Dec 2025
Pontifax Management 4 G.P. (2015) Ltd. 7.7% $12,911,822 5,206,380 Pontifax VI G.P. L.P. 27 Jun 2024
MPM BioImpact LLC 5.6% $13,437,544 2,671,480 MPM BioImpact LLC 31 Dec 2025

As of 31 Dec 2025, 63 institutional investors reported holding 28,719,480 shares of Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM). This represents 60% of the company’s total 47,705,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM) together control 56% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 18% 8,813,956 -72% 0.36% $35,255,824
MPM BIOIMPACT LLC 5.6% 2,671,480 1.2% $10,685,920
PRICE T ROWE ASSOCIATES INC /MD/ 4% 1,923,639 +265% 0% $7,695,000
ADAR1 Capital Management, LLC 3% 1,432,475 +973% 0.43% $5,729,900
VANGUARD GROUP INC 2.8% 1,340,504 +1.9% 0% $5,362,016
Affinity Asset Advisors, LLC 2.7% 1,300,000 0% 0.37% $5,200,000
Kynam Capital Management, LP 2.2% 1,028,341 0% 0.27% $4,113,364
GREAT POINT PARTNERS LLC 2.1% 979,534 1.3% $3,918,136
SPHERA FUNDS MANAGEMENT LTD. 2% 932,247 +114% 0.78% $3,728,988
Point72 Asset Management, L.P. 1.5% 716,680 0% $2,866,720
Driehaus Capital Management LLC 1.3% 600,946 0.02% $2,403,784
TWO SIGMA INVESTMENTS, LP 1.2% 566,712 +403% 0% $2,266,848
Peapod Lane Capital LLC 1.2% 565,992 +0.73% 1.9% $2,263,968
NAN FUNG TRINITY (HK) LTD 0.97% 463,654 0% 0.15% $1,854,616
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.93% 445,342 +213% 0% $1,781,368
KOTLER KEVIN 0.84% 400,000 0% 1.2% $1,600,000
BlackRock, Inc. 0.82% 389,309 -47% 0% $1,557,236
RENAISSANCE TECHNOLOGIES LLC 0.67% 320,600 -40% 0% $1,282,400
GEODE CAPITAL MANAGEMENT, LLC 0.65% 310,756 -0.31% 0% $1,243,615
MARSHALL WACE, LLP 0.64% 304,015 +32% 0% $1,216,060
MILLENNIUM MANAGEMENT LLC 0.62% 296,314 -37% 0% $1,185,256
TD Asset Management Inc 0.52% 246,200 +175% 0% $984,800
CITADEL ADVISORS LLC 0.5% 239,043 0% $956,172
GOLDMAN SACHS GROUP INC 0.47% 224,883 +205% 0% $899,532
683 Capital Management, LLC 0.42% 201,652 0.07% $806,608

Institutional Holders of Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 28,719,480 $114,894,226 -$59,704,101 $4.00 63
2025 Q3 44,576,107 $89,598,934 -$10,311,694 $2.01 66
2025 Q2 49,893,947 $61,871,600 -$2,503,034 $1.24 68
2025 Q1 51,939,064 $63,368,269 -$8,741,696 $1.22 76
2024 Q4 55,706,408 $100,272,719 -$19,354,214 $1.80 78
2024 Q3 54,655,767 $278,130,509 +$14,600,273 $5.09 69
2024 Q2 49,901,732 $354,801,793 +$245,093,722 $7.11 46
2024 Q1 16,855,387 $46,194,788 +$5,051 $2.74 20
2023 Q4 16,853,724 $45,505,627 +$348,407 $2.70 22
2023 Q3 16,728,590 $43,997,383 -$6,828 $2.63 22
2023 Q2 16,730,361 $46,844,345 +$79,298 $2.80 21
2023 Q1 16,702,070 $48,434,001 +$194,589 $2.90 19
2022 Q4 16,628,134 $61,000,699 +$90,854 $3.67 20
2022 Q3 14,807,225 $47,821,510 -$982,037 $3.23 20
2022 Q2 15,127,218 $45,689,000 -$21,553,504 $3.02 22
2022 Q1 17,488,772 $146,733,000 +$663,723 $8.39 40
2021 Q4 17,373,074 $181,720,000 +$142,325 $10.46 34
2021 Q3 17,279,112 $310,677,000 +$310,677,000 $17.98 31